Natural Product (NP) Details
| General Information of the NP (ID: NP4440) | |||||
|---|---|---|---|---|---|
| Name |
Kaempferol
|
||||
| Synonyms |
kaempferol; 520-18-3; Kaempherol; Kempferol; Trifolitin; Populnetin; Robigenin; Rhamnolutein; Pelargidenolon; Rhamnolutin; Swartziol; Indigo Yellow; Kampherol; Nimbecetin; Kampferol; Campherol; Kaemferol; 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; 5,7,4'-Trihydroxyflavonol; Pelargidenolon 1497; 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; C.I. 75640; CCRIS 41; NSC 407289; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)chromen-4-one; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxyphe
Click to Show/Hide
|
||||
| Species Origin | Equisetum hyemale ... | Click to Show/Hide | |||
| Equisetum hyemale | |||||
| Nelumbo nucifera | |||||
| Camellia japonica | |||||
| Potentilla indica | |||||
| Adiantum capillus-veneris | |||||
| Camptotheca acuminata | |||||
| Cibotium barometz | |||||
| Patrinia rupestris | |||||
| Impatiens balsamina | |||||
| Asplenium prolongatum | |||||
| Kalanchoe pinnata | |||||
| Orostachys fimbriata | |||||
| Litsea glutinosa | |||||
| Melia azedarach | |||||
| Equisetum ramosissimum | |||||
| Microcos paniculata | |||||
| Indigofera tinctoria | |||||
| Euscaphis japonica | |||||
| Hypericum ascyron | |||||
| Lysimachia christinae | |||||
| Inula japonica | |||||
| Euphorbia lunulata | |||||
| Lespedeza thunbergii | |||||
| Clematis aethusifolia | |||||
| Lysimachia barystachys | |||||
| Disease | Stomach cancer [ICD-11: 2B72] | Investigative | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C15H10O6
|
||||
| PubChem CID | |||||
| Canonical SMILES |
C1=CC(=CC=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O
|
||||
| InChI |
1S/C15H10O6/c16-8-3-1-7(2-4-8)15-14(20)13(19)12-10(18)5-9(17)6-11(12)21-15/h1-6,16-18,20H
|
||||
| InChIKey |
IYRMWMYZSQPJKC-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 520-18-3
|
||||
| Herb ID | |||||
| ETMC ID | |||||
| SymMap ID | |||||
| TCMSP ID | |||||
| TTD Drug ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| Cisplatin | Bladder cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | MYC | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | OVCAR-3 | CVCL_0465 | Ovarian serous adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Kaempferol enhances cisplatin's effect on ovarian cancer cells through promoting apoptosis caused by down regulation of cMyc. | |||||
| TNF-related apoptosis inducing ligand | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | TRAIL-R1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | TRAIL-R2 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | SW480 | CVCL_0546 | Colon adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Kaempferol sensitizes colon cancer cells to TRAIL-induced apoptosis. | |||||
| Sorafenib | Renal cell carcinoma | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [4] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | ABCB1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
| N1S1 | Hepatocellular carcinoma | Rattus norvegicus | ||||
| Experimental
Result(s) |
Kaempferol-mediated sensitization enhances chemotherapeutic efficacy of sorafenib against hepatocellular carcinoma. | |||||
| 5-fluorouracil | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [5] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HCT 8 | CVCL_2478 | Colon adenocarcinoma | Homo sapiens | ||
| HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Kaempferol has a synergistic effect with 5-FU by inhibiting cell proliferation and inducing apoptosis in colorectal cancer cells via suppression of TS or attenuation of p-Akt activation. | |||||
| Doxorubicin | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [6] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | MMP-9 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | mTOR | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | PIK3CB | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | Huh-7 | CVCL_0336 | Adult hepatocellular carcinoma | Homo sapiens | ||
| HuH-1 | CVCL_2956 | Adult hepatocellular carcinoma | Homo sapiens | |||
| Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | |||
| Hep-G2/2.2.15 | CVCL_L855 | Hepatoblastoma | Homo sapiens | |||
| SK-HEP-1 | CVCL_0525 | Hepatocellular carcinoma | Homo sapiens | |||
| PLC/PRF/5 | CVCL_0485 | Adult hepatocellular carcinoma | Homo sapiens | |||
| HLE | CVCL_1281 | Adult hepatocellular carcinoma | Homo sapiens | |||
| HLF | CVCL_2947 | Adult hepatocellular carcinoma | Homo sapiens | |||
| Hep 3B2.1-7 | CVCL_0326 | Childhood hepatocellular carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Kaempferol exhibits a synergistic effect with doxorubicin to inhibit proliferation, migration, and invasion of liver cancer. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Aldose reductase (AKR1B1) | Molecule Info | [7] | |
| Androgen receptor (AR) | Molecule Info | [8] | ||
| Arachidonate 15-lipoxygenase (15-LOX) | Molecule Info | [9] | ||
| Cytochrome P450 1B1 (CYP1B1) | Molecule Info | [10] | ||
| Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) | Molecule Info | [11] | ||
| Influenza Neuraminidase (Influ NA) | Molecule Info | [12] | ||
| Lactoylglutathione lyase (GLO1) | Molecule Info | [13] | ||
| Plasmodium 3-oxoacyl-acyl-carrier reductase (Malaria fabG) | Molecule Info | [14] | ||
| BioCyc | Methylglyoxal degradation III | Click to Show/Hide | ||
| 2 | Acetone degradation I (to methylglyoxal) | |||
| 3 | Superpathway of tryptophan utilization | |||
| 4 | Superpathway of melatonin degradation | |||
| 5 | Melatonin degradation I | |||
| 6 | Superpathway of steroid hormone biosynthesis | |||
| 7 | Estradiol biosynthesis I | |||
| 8 | Methylglyoxal degradation I | |||
| 9 | Resolvin D biosynthesis | |||
| 10 | Lipoxin biosynthesis | |||
| KEGG Pathway | Oocyte meiosis | Click to Show/Hide | ||
| 2 | Pathways in cancer | |||
| 3 | Prostate cancer | |||
| 4 | Pentose and glucuronate interconversions | |||
| 5 | Fructose and mannose metabolism | |||
| 6 | Galactose metabolism | |||
| 7 | Glycerolipid metabolism | |||
| 8 | Metabolic pathways | |||
| 9 | Steroid hormone biosynthesis | |||
| 10 | Tryptophan metabolism | |||
| 11 | Metabolism of xenobiotics by cytochrome P450 | |||
| 12 | Ovarian steroidogenesis | |||
| 13 | Chemical carcinogenesis | |||
| 14 | MicroRNAs in cancer | |||
| 15 | Pyruvate metabolism | |||
| 16 | Arachidonic acid metabolism | |||
| 17 | Linoleic acid metabolism | |||
| 18 | Serotonergic synapse | |||
| 19 | Other glycan degradation | |||
| NetPath Pathway | EGFR1 Signaling Pathway | Click to Show/Hide | ||
| 2 | AndrogenReceptor Signaling Pathway | |||
| 3 | FSH Signaling Pathway | |||
| 4 | IL1 Signaling Pathway | |||
| 5 | TGF_beta_Receptor Signaling Pathway | |||
| 6 | TSH Signaling Pathway | |||
| 7 | IL4 Signaling Pathway | |||
| 8 | TCR Signaling Pathway | |||
| Panther Pathway | Androgen/estrogene/progesterone biosynthesis | Click to Show/Hide | ||
| 2 | Inflammation mediated by chemokine and cytokine signaling pathway | |||
| Pathwhiz Pathway | Fructose and Mannose Degradation | Click to Show/Hide | ||
| 2 | Pyruvate Metabolism | |||
| 3 | Pterine Biosynthesis | |||
| 4 | Glycerolipid Metabolism | |||
| 5 | Galactose Metabolism | |||
| 6 | Androgen and Estrogen Metabolism | |||
| 7 | Pyruvaldehyde Degradation | |||
| 8 | Arachidonic Acid Metabolism | |||
| Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | Click to Show/Hide | ||
| 2 | Coregulation of Androgen receptor activity | |||
| 3 | Regulation of Androgen receptor activity | |||
| 4 | Nongenotropic Androgen signaling | |||
| 5 | Regulation of nuclear beta catenin signaling and target gene transcription | |||
| 6 | FOXA1 transcription factor network | |||
| 7 | Notch-mediated HES/HEY network | |||
| 8 | IL4-mediated signaling events | |||
| Reactome | Nuclear Receptor transcription pathway | Click to Show/Hide | ||
| 2 | Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | |||
| 3 | Endogenous sterols | |||
| 4 | The canonical retinoid cycle in rods (twilight vision) | |||
| 5 | Pyruvate metabolism | |||
| WikiPathways | SIDS Susceptibility Pathways | Click to Show/Hide | ||
| 2 | Integrated Pancreatic Cancer Pathway | |||
| 3 | Prostate Cancer | |||
| 4 | Integrated Breast Cancer Pathway | |||
| 5 | Nuclear Receptors | |||
| 6 | Androgen receptor signaling pathway | |||
| 7 | Metapathway biotransformation | |||
| 8 | Polyol Pathway | |||
| 9 | Metabolism of steroid hormones and vitamin D | |||
| 10 | Estrogen metabolism | |||
| 11 | Benzo(a)pyrene metabolism | |||
| 12 | Tamoxifen metabolism | |||
| 13 | Tryptophan metabolism | |||
| 14 | Oxidation by Cytochrome P450 | |||
| 15 | Nuclear Receptors Meta-Pathway | |||
| 16 | Estrogen Receptor Pathway | |||
| 17 | Sulindac Metabolic Pathway | |||
| 18 | Arylhydrocarbon receptor (AhR) signaling pathway | |||
| 19 | miR-targeted genes in muscle cell - TarBase | |||
| 20 | miR-targeted genes in lymphocytes - TarBase | |||
| 21 | miR-targeted genes in epithelium - TarBase | |||
| 22 | miR-targeted genes in adipocytes - TarBase | |||
| 23 | Phase 1 - Functionalization of compounds | |||
| 24 | Steroid Biosynthesis | |||
| 25 | Arachidonic acid metabolism | |||
| 26 | Eicosanoid Synthesis | |||
